Clinical Trials Directory

Trials / Completed

CompletedNCT00003887

Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation

Donor Lymphocyte Infusion (DLI) as Adoptive Immunotherapy for Relapse Malignancies After Allogeneic Hematopoietic Transplantation

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
—
Sponsor
Fred Hutchinson Cancer Center · Academic / Other
Sex
All
Age
1 Year – 70 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: White blood cells from donors may be able to kill cancer cells in patients with cancer that has recurred following bone marrow or peripheral stem cell transplantation. PURPOSE: Phase II trial to study the effectiveness of donated white blood cells in treating patients who have relapsed cancer following transplantation of donated bone marrow or peripheral stem cells.

Detailed description

OBJECTIVES: I. Offer donor lymphocyte infusion as adoptive immunotherapy in patients with relapsed malignancies after allogeneic bone marrow or peripheral blood stem cell transplantation and who are not eligible for other FHCRC protocols. OUTLINE: Patients with rapidly progressive disease receive reinduction chemotherapy and radiotherapy prior to study therapy. Donor lymphocyte infusions (DLI) begin after recovery from chemotherapy or sooner, if clinically indicated. Patients receive 1 or more DLI from the original donor. Patients are followed monthly for 3 months, then every 3-6 months for 9 months. PROJECTED ACCRUAL: An unlimited number of patients will be accrued for this study.

Conditions

Interventions

TypeNameDescription
BIOLOGICALperipheral blood lymphocyte therapy

Timeline

Start date
1998-08-01
Completion
2003-02-01
First posted
2004-04-27
Last updated
2011-11-30

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00003887. Inclusion in this directory is not an endorsement.